In the MAHALO phase 2 trial (Genentech) in geographic atrophy, the CFD inhibitor, lampalizumab, slowed disease progression most prominently in individuals with a particular genetic makeup which notably linked to a polymorphism in the CFI gene [33]. The gene discussed is CFI; the disease is atrophic macular degeneration.